Skip to main
GENB

GENB Stock Forecast & Price Target

GENB Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Generate Biomedicines is positioned for future success with promising drugs in their pipeline and a strong financial standing. However, they face competition and potential challenges that may impact their success. Their AI platform and potential for reduced toxicity in ADC therapies provide a unique advantage in the biotech industry.

Bears say

Generate Biomedicines is a clinical-stage generative biology company that primarily relies on its AI platform, Generate, to design protein therapeutics for various indications. Despite the promising preclinical and clinical data for its lead candidate, GB-0895, there are significant risks and uncertainties, such as competition from larger and well-established companies with potentially greater resources, that could hinder the company's future success. Moreover, the company's valuation is heavily dependent on the success of GB-0895 and other product candidates in the pipeline, which may not be guaranteed given the competitive landscape and potential for clinical failure.

GENB has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Generate Biomedicines Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Generate Biomedicines Inc (GENB) Forecast

Analysts have given GENB a Strong Buy based on their latest research and market trends.

According to 5 analysts, GENB has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Generate Biomedicines Inc (GENB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.